Our Story

Sometimes a fresh perspective on something we thought we understood, can open the door to new possibilities we hadn’t even considered.

Focused on pioneering medical device innovation, Spectrum Solutions commissioned the breakthrough saliva study that dared to suggest a complete transformation in viral PCR testing protocols to an easier, pain-free, non-invasive, 99.998% accurate, and infinitely safer option using saliva (spit).

Saliva’s recent MVP status is a new development even though saliva’s been used in diagnostics for more than 2000 years. Analysis of the properties in saliva using biochemical and physiological methodologies are traced back to at least a century ago. Unlike blood, saliva analysis looks at the cellular level (the biologically active compounds), making it a better representative of what is clinically relevant.

Years from now, the medical community, patients, and history books will look back on 2020 and COVID-19 testing as the diagnostic turning point in favor of saliva.

In affirmation of this diagnostic innovation pivot, a speedy and unprecedented FDA response secured the first Emergency Use Authorization (EUA) early March 2020, for the use of saliva, solely collected using the Spectrum SDNA-1000, as a diagnostic biomaterial for COVID-19 testing.

A few weeks later, requests for additional product and process information to further validate safety and sample efficacy in extended storage and transport scenarios. The device’s remarkable performance locked in the FDA’s first direct-to-patient at-home testing authorization for the self-collection of saliva. A timely decision that drove product integration both nationwide and globally.

Saliva collected using a Spectrum bio-sample collection system creates the most robust and safest testing biomaterial paving the way to a new era of at-home and direct-to-consumer molecular diagnostic testing for viral infections, autoimmune disorders, cancer, and more.

#partoftheSolution

Kudos & Press Releases

Follow These Leaders

Make the switch and integrate better molecular diagnostic collection products, services, and customized solutions for fast project success.

Stephen J. Fanning

CHIEF EXECUTIVE OFFICER and PRESIDENT

Mr. Fanning has a rich track record of leading successful companies in the life sciences space. Prior to joining Spectrum DNA, he was President and CEO of Z-Medica Corporation, President and CEO of Solta Medical, Inc. (formerly Thermage, Inc.) and served in various senior executive positions at Johnson & Johnson for 25 years. Among his additional titles are President, Worldwide, of J&J’s McNeil Specialty Products division and President of Johnson & Johnson Medical. He currently serves on the board of three other medical and manufacturing companies.

Bill Phillips

CHIEF OPERATING OFFICER

As a founding partner of Spectrum Solutions, Mr. Phillips has spent 21 years focused on customer packaging, product engineering, and building an innovative customer-focused company. Under his leadership the company grew and evolved from the original two individuals to several hundred employees. His professional creativity and vast product manufacturing knowledge have earned him several industry awards and accolades as well as patents.

David Colbert

CHIEF FINANCIAL OFFICER

Mr. Colbert joined Spectrum Solutions as Chief Financial Officer in August 2019. He has a wide breadth of corporate finance experience for both public and private firms. Prior to joining Spectrum, he was CFO at Clayton Holdings, CFO of LifeVantage Corporation, and CFO of Park City Group and Co-founder and Chief Financial Officer for Sendside Networks, Inc. He began his career at Kimberly-Clark Corporation where he spent 13 years primarily within the medical supplies and device division.

Dr. David J. Vigerust

CHIEF SCIENCE OFFICER

Dr. David J. Vigerust, MS., PhD., Spectrum’s Chief Scientific Officer, has a deep foundational and highly practical scientific knowledge across multiple disciplines in biotechnology, medicine, and life science. Dr. Vigerust holds a bachelor’s degree in biology and chemistry from the University of Texas at El Paso, a master’s degree in microbiology and immunology from Texas Tech University in Lubbock, and a Ph.D. in cellular and molecular pathology from Vanderbilt University in Nashville, TN.  Additionally, Dr. Vigerust conducted his post-doctoral research on viral glycosylation, host defense from influenza, and bacterial secondary infection in the Department of Infectious Disease at St. Jude Children’s Research Hospital. He completed a second post-doctoral fellowship at Vanderbilt University Medical School in the Department of Pediatric Infectious Disease in the area of molecular biology of respiratory viruses.

Rohit Gupta

CHIEF MEDICAL OFFICER

Mr. Rohit Gupta joined Spectrum Solutions as Chief Medical in the early first quarter of 2021. Rohit additionally became a member of Spectrum’s scientific advisory board in 2020 currently now serving as Board Chair. Concurrent to his position at Spectrum Solutions, Rohit also serves as the Chief Biobank Officer for TMRW Life Sciences. Rohit will be responsible for the strategy, direction, and execution of Spectrum’s clinical and medical product development plans. Rohit’s leadership will steer Spectrum’s R&D efforts and continue to drive product innovation.

Stephen J. Fanning

CHIEF EXECUTIVE OFFICER and PRESIDENT

Mr. Fanning has a rich track record of leading successful companies in the life sciences space. Prior to joining Spectrum DNA, he was President and CEO of Z-Medica Corporation, President and CEO of Solta Medical, Inc. (formerly Thermage, Inc.) and served in various senior executive positions at Johnson & Johnson for 25 years. Among his additional titles are President, Worldwide, of J&J’s McNeil Specialty Products division and President of Johnson & Johnson Medical. He currently serves on the board of three other medical and manufacturing companies.

Bill Phillips

CHIEF OPERATING OFFICER

As a founding partner of Spectrum Solutions, Mr. Phillips has spent 21 years focused on customer packaging, product engineering, and building an innovative customer-focused company. Under his leadership the company grew and evolved from the original two individuals to several hundred employees. His professional creativity and vast product manufacturing knowledge have earned him several industry awards and accolades as well as patents.

David Colbert

CHIEF FINANCIAL OFFICER

Mr. Colbert joined Spectrum Solutions as Chief Financial Officer in August 2019. He has a wide breadth of corporate finance experience for both public and private firms. Prior to joining Spectrum, he was CFO at Clayton Holdings, CFO of LifeVantage Corporation, and CFO of Park City Group and Co-founder and Chief Financial Officer for Sendside Networks, Inc. He began his career at Kimberly-Clark Corporation where he spent 13 years primarily within the medical supplies and device division.

Dr. David J. Vigerust

CHIEF SCIENCE OFFICER

Dr. David J. Vigerust, MS., PhD., Spectrum’s Chief Scientific Officer, has a deep foundational and highly practical scientific knowledge across multiple disciplines in biotechnology, medicine, and life science. In addition to his role at Spectrum, Dr. Vigerust currently holds an Adjunct Assistant Professor position at Vanderbilt University Medical Center in the Department of Neurological Surgery as well as a Clinical Assistant Professor with the University of Maryland, Eastern Shore School of Pharmacy. Throughout his career, he has developed several novel molecular diagnostic assays for the prediction of cardiovascular risk in patients with diabetes, infectious disease, and cancer.

Rohit Gupta

CHIEF MEDICAL OFFICER

Mr. Rohit Gupta joined Spectrum Solutions as Chief Medical in the early first quarter of 2021. Rohit additionally became a member of Spectrum’s scientific advisory board in 2020 currently now serving as Board Chair. Concurrent to his position at Spectrum Solutions, Rohit also serves as the Chief Biobank Officer for TMRW Life Sciences. Rohit will be responsible for the strategy, direction, and execution of Spectrum’s clinical and medical product development plans. Rohit’s leadership will steer Spectrum’s R&D efforts and continue to drive product innovation.

Our Team, Helping your Team, get Back in the Game!

How you collect saliva makes a big diagnostic difference. Saliva collected using the Spectrum bio-sample collection system creates the most robust and safest testing biomaterial paving the way to a new era of at-home and direct-to-consumer molecular diagnostic testing for viral infections, autoimmune disorders, cancer, and more.

blank

PROUD PARTNER OF MLB

™/© 2020 MLB

Spectrum
in the News

Spectrum
in the News

Let’s Connect

Ready to Advance your Medical Device Program?

Fully integrated industry experts create forward-looking end-to-end solutions. Your competitive advantage awaits.

Spectrum Solutions Commercial Product Innovation

Ready to advance your medical device program?

Fully integrated industry experts create forward-looking end-to-end solutions. Your competitive advantage awaits.